| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
hsa-miR-98-5p, hsa-miR-615-5p, hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p |
| Biological function: |
Associated with gefitinib resistance and with advanced stage/lymph node metastasis; suggested involvement in NSCLC growth, progression and migration. |
| Molecular mechanism: |
Predicted miRNA sponging with five miRNAs (TargetScan/miRanda-based prediction); downstream targets not experimentally validated. |
| Biological pathway or process: |
ceRNA regulation (other); drug resistance (promotes); metastasis (other); migration (other); proliferation (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; Clinical Sample Validation; ROC Analysis; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Diagnostic biomarker with AUC 0.89; high expression associated with shortened OS and DFS/PFS and poor prognosis. |
| Description: |
hsa_circRNA_012515 (host gene PANX2) is significantly up-regulated in NSCLC tissues, NSCLC cell lines, and gefitinib-resistant samples. High expression shows diagnostic value (ROC AUC 0.89) and is associated with advanced stage/lymph node metastasis and worse survival outcomes. Its mechanism was explored by bioinformatic prediction suggesting interaction with five miRNAs, but downstream targets were not experimentally validated. |
| Confidence score: |
0.636 |